AEON Biopharma (NASDAQ:AEON) Stock Rating Reaffirmed by HC Wainwright

AEON Biopharma (NASDAQ:AEON)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 466.04% from the stock’s previous close.

AEON Biopharma Stock Performance

Shares of AEON Biopharma stock opened at $1.06 on Wednesday. The firm’s 50-day simple moving average is $1.41 and its 200-day simple moving average is $6.27. AEON Biopharma has a 1 year low of $0.92 and a 1 year high of $17.17.

AEON Biopharma (NASDAQ:AEON) last issued its earnings results on Tuesday, May 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. As a group, equities research analysts expect that AEON Biopharma will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AEON Biopharma stock. Vanguard Group Inc. increased its position in AEON Biopharma, Inc. (NASDAQ:AEON) by 261.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 758,992 shares of the company’s stock after purchasing an additional 549,207 shares during the period. Vanguard Group Inc. owned about 2.01% of AEON Biopharma worth $8,804,000 at the end of the most recent reporting period. 22.78% of the stock is currently owned by institutional investors.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.